Solid Tumors Clinical Trial
Official title:
A First in Human Phase I Study of INVAC-1 as a Single Agent in Patients With Advanced Cancer
Verified date | February 2019 |
Source | Invectys |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
INVAC-1 is intended to be used for the treatment of adult patients with advanced solid tumors unresponsive to currently available therapies, or for whom no standard therapy is available.
Status | Completed |
Enrollment | 26 |
Est. completion date | June 1, 2018 |
Est. primary completion date | February 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Histological diagnosis of advanced/metastatic solid tumor malignancy - Relapsed or refractory to standard treatment and for whom standard curative options do not exist - Life-expectancy > 4 months - Age 18 years or older - Eastern Cooperative Oncology Group (ECOG) performance status =1 - A delay of at least 3 weeks between last specific anticancer treatment and first INVAC-1 injection - Adequate skin status - Lack of biologically documented inflammation: C Reactive Protein < 15 mg/L - No medical history of auto-immune disease - Adequate bone marrow function - Total white cells count = 10 x 109/L (= 10,000/µL), - Serum albuminemia > 30 g/L - Adequate renal function, with an estimated creatinine clearance = 50 mL/min as calculated using the Cockroft & Gault method - Adequate liver function - Adequate cardiac function - Resolved acute effects of any prior therapy to baseline severity or Grade = 1 CTCAE v. 4.03 except for Adverse Events not constituting a safety risk by investigator judgment - Lack of immune-suppressive drugs and of high-dose corticoid treatment within 8 weeks prior to entering the study (prednisone or prednisolone = 10 mg/day is allowed) - Serum pregnancy test (for females of childbearing potential) negative within 7 days of first dose of study drug - Female patients must be surgically sterile or be postmenopausal, or must agree to use effective contraception during the period of the trial and for at least 90 days after completion of treatment. Male patients must be surgically sterile or must agree to use effective contraception during the period of the trial and for at least 90 days after completion of treatment. The decision of effective contraception will be based on the judgment of the principal investigator. - Provision of written informed consent indicating that the patient has been informed of all the pertinent aspects of the trial to be followed - Willingness and ability to comply with the study scheduled visits, treatment plans, laboratory tests and other procedures. Exclusion Criteria: - Central Nervous System (CNS) primary or CNS metastatic malignancies - Prior allogeneic hematopoietic stem cell transplant - Chemotherapy, cancer immunosuppressive therapy, growth factors, systemic steroids, or investigational agents within 28 days before the first dose of study treatment - Prior therapy with a compound of the same mechanism (immunomodulation) in the last 90 days prior to first dose of study drug - Participation to a clinical trial of an experimental medication in the last 30 days prior to first dose of study drug - Major surgery within 28 days of starting study treatment - Radiation therapy within 28 days of starting study treatment - Autoimmune disorders (eg, Crohn's Disease, rheumatoid arthritis, scleroderma, systemic lupus erythematosus) and other diseases that compromise or impair the immune system. - Contra-indications to electroporation: cardiac pacemaker, any previous cardiac rhythm disorder, epilepsy. - Active and clinically significant bacterial, fungal or viral infection including hepatitis B (HBV), hepatitis C (HCV), known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness (HIV testing is not required). - Unstable or serious concurrent medical conditions in the previous 12 months. - Concurrent active malignancy other than non-melanoma skin cancer or carcinoma in situ of the cervix. - Patients who are pregnant or breastfeeding. - Other severe acute or chronic medical or psychiatric condition or laboratory abnormality. - Patients who are investigational site staff members or patients who are Invectys employees directly involved in the conduct of the trial. |
Country | Name | City | State |
---|---|---|---|
France | Hôpital Européen Georges Pompidou | Paris | |
France | Hôpital Saint Louis | Paris |
Lead Sponsor | Collaborator |
---|---|
Invectys | Keyrus Biopharma |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Dose Limiting Toxicities (DLTs) of INVAC-1 as single agent in combination with electroporation | up to 28 days after last injection | ||
Secondary | Adverse Events as characterized by type, frequency, severity (as graded by NCI Common Toxicity Criteria for Adverse Effects (CTCAE) v.4.03), timing, seriousness and relationship to study therapy INVAC-1 + electroporation; | up to 28 days after last injection | ||
Secondary | Routine laboratory abnormalities as characterized by type, frequency, severity (as graded by NCI CTCAE v.4.03) and timing | up to 28 days after last injection | ||
Secondary | Tumor Necrosis Factor-a, Interleukine (IL)-17, IL-8, IL-6, IL-1ß measured in serum | up to 28 days after last injection | ||
Secondary | anti-nuclear antibodies (ANA), anti-DNA, anti-TPO measured in serum | up to 28 days after last injection | ||
Secondary | Elispot Interferon gamma | every 4 weeks up to 3 months | ||
Secondary | Absolute cell counts and phenotype for circulating T and Natural Killer cells | every 2 weeks up to 3 months | ||
Secondary | circulating tumor DNA assessed by quantification of the allelic fraction of the DNA mutations; circulating DNA is extracted from plasma | before treatment; at day 15 of cycle 3 | ||
Secondary | Objective response assessed by immune-related Response Criteria (ir-RC); | every 8 weeks during treatement and every 2 to 4 months during one-year follow-up | ||
Secondary | Duration of response | every 8 weeks during treatement and every 2 to 4 months during one-year follow-up | ||
Secondary | Progression free survival | approximately 15 months | ||
Secondary | Overall survival | approximately 15 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT00750841 -
Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours
|
Phase 1 | |
Withdrawn |
NCT05419817 -
Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System
|
Phase 2 | |
Completed |
NCT02828930 -
A Study to Determine the Excretion Balance, Pharmacokinetics, Metabolism and Absolute Oral Bioavailability of a Single Oral Dose of [14C]-Labeled Idasanutlin and an Intravenous Tracer Dose of [13C]-Labeled Idasanutlin in a Single Cohort of Participants With Solid Tumors (Malignancies)
|
Phase 1 | |
Completed |
NCT01197170 -
Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance
|
Phase 1 | |
Completed |
NCT03258515 -
A Study to Investigate the Effect of Single Dose of AZD6094 (600 mg) on Cardiac Repolarization in Healthy Volunteers
|
Phase 1 | |
Terminated |
NCT03225105 -
M3541 in Combination With Radiotherapy in Solid Tumors
|
Phase 1 | |
Completed |
NCT01497925 -
Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer
|
Phase 1 | |
Completed |
NCT01878890 -
Phase I Dose Escalation Trial of Efavirenz in Solid Tumours or Non-Hodgkin Lymphoma in Therapeutic Failure.
|
Phase 1 | |
Active, not recruiting |
NCT05059522 -
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
|
Phase 3 | |
Active, not recruiting |
NCT03634982 -
Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors
|
Phase 1 | |
Recruiting |
NCT04685226 -
A Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
Recruiting |
NCT06036121 -
A Study of ADRX-0706 in Select Advanced Solid Tumors
|
Phase 1 | |
Active, not recruiting |
NCT03258151 -
Association of Genetic Polymorphisms With Docetaxel-based Chemotherapy Toxicities in Chinese Solid Tumor Patients
|
||
Completed |
NCT01528046 -
Metformin in Children With Relapsed or Refractory Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05325866 -
A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
|
Phase 1/Phase 2 | |
Recruiting |
NCT04557449 -
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT02759640 -
A Phase I Trial of HS-10241 in Solid Tumors
|
Phase 1 | |
Terminated |
NCT02890368 -
Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides
|
Phase 1 | |
Completed |
NCT02279433 -
A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b
|
Phase 1 |